Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 25;6:32036. doi: 10.1038/srep32036

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(A) Effect of exactin (1 μM to 300 μM) on the coagulation of human plasma: prothrombin time (■), Stypven time (♦), APTT (●) and thrombin time (▲). (B) Identification of specific site of action of exactin. Effect of exactin on reconstituted ETC (■), intrinsic tenase complex (●), prothrombinase complex (▼) and thrombin (▲). (C) Mechanism of inhibition of the extrinsic tenase complex. The effect of exactin on the sequential removal of each component of the ETC: removal of TF [FVIIa/FX/phospholipids (●)] and phospholipids [FVIIa/sTF/FX (▲)] compared to full complex [FVIIa/TF/FX/phospholipids (■)]. For comparison, dose-response curve of the effect of exactin on ETC is shown in dotted line. (D) Effect of exactin on hydrolysis of small peptides. The effect of exactin on amidolytic activity of FVIIa (●), FVIIa/sTF (■), and FVIIa/phospholipids (▲). Each data point represents the average ± SD of three independent experiments.